loader
Please Wait
Applying Filters...

Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Canertinib, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Canertinib

    INTERMEDIATES

    PharmaCompass

    Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.

    One Pharma aims to be one of the leading generic companies in Europe.

    2D Structure
    1. Also known as: 267243-28-7, Ci-1033, Pd-183805, Canertinib (ci-1033), Canertinib free base, N-(4-(3-chloro-4-fluorophenylamino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide
    Molecular Formula
    C24H25ClFN5O3
    Molecular Weight
    485.9  g/mol
    InChI Key
    OMZCMEYTWSXEPZ-UHFFFAOYSA-N
    FDA UNII
    C78W1K5ASF
    Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide
    2.1.2 InChI
    InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)
    2.1.3 InChI Key
    OMZCMEYTWSXEPZ-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
    2.2 Other Identifiers
    2.2.1 UNII
    C78W1K5ASF
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Ci 1033

    2. Ci-1033

    3. Ci1033

    2.3.2 Depositor-Supplied Synonyms

    1. 267243-28-7

    2. Ci-1033

    3. Pd-183805

    4. Canertinib (ci-1033)

    5. Canertinib Free Base

    6. N-(4-(3-chloro-4-fluorophenylamino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide

    7. N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide

    8. C78w1k5asf

    9. Chembl31965

    10. N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide

    11. Chebi:61399

    12. 267243-28-7 (free Base)

    13. N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide

    14. Ncgc00182713-01

    15. Pd183805

    16. Canertinib [inn]

    17. Canertinib [inn:ban]

    18. Sn-26606

    19. Ci-1033(canertinib)

    20. Ci1033

    21. Unii-c78w1k5asf

    22. Canetinib

    23. Canertinib [mi]

    24. Caneritinib; Ci-1033

    25. Canertinib - Ci-1033

    26. Ci-1033 (canertinib)

    27. Canertinib [who-dd]

    28. Dsstox_cid_28869

    29. Dsstox_rid_83138

    30. Dsstox_gsid_48943

    31. Schembl54837

    32. Mls004774146

    33. Pd 183805 Dihydrochloride

    34. Bdbm4779

    35. Cid_156414

    36. Gtpl5675

    37. Dtxsid8048943

    38. Ex-a078

    39. Bcpp000301

    40. Hms3244m17

    41. Hms3244m18

    42. Hms3244n17

    43. Bcp01790

    44. Tox21_113361

    45. Nsc780019

    46. Nsc801011

    47. S1019

    48. Zinc27439698

    49. Akos005145818

    50. Bcp9000481

    51. Bcp9000482

    52. Bcp9000525

    53. Ccg-269588

    54. Cs-0121

    55. Db05424

    56. Nsc-780019

    57. Nsc-801011

    58. Sb16594

    59. N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide

    60. N-[4-(3-chloro-4-fluoro-anilino)-7-(3-morpholinopropoxy)quinazolin-6-yl]prop-2-enamide

    61. Ncgc00182713-02

    62. Ncgc00182713-18

    63. As-56189

    64. Hy-10367

    65. Smr003500789

    66. Pd0183805

    67. Cas-267243-28-7

    68. Ft-0654215

    69. Ec-000.2258

    70. A25038

    71. 499c452

    72. Q5032274

    73. 2-propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-

    74. N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide

    75. N-[4-(3-chloro-4-fluoro-phenyl-amino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide

    2.4 Create Date
    2005-08-08
    3 Chemical and Physical Properties
    Molecular Weight 485.9 g/mol
    Molecular Formula C24H25ClFN5O3
    XLogP33.9
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count9
    Exact Mass485.1629955 g/mol
    Monoisotopic Mass485.1629955 g/mol
    Topological Polar Surface Area88.6 Ų
    Heavy Atom Count34
    Formal Charge0
    Complexity671
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Investigated for use/treatment in breast cancer and lung cancer.

    5 Pharmacology and Biochemistry
    5.1 Mechanism of Action

    CI-1033 effectively inhibits the growth of esophageal squamous cell carcinoma which co-expresses both EGFR and HER2 with the inhibition of phosphorylation of both MAPK and AKT. Some studies suggest that CI-1033 holds significant clinical potential in esophageal cancer.

    Post Enquiry
    POST ENQUIRY